Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GSK Launches An Operations Revamp

November 5, 2007 | A version of this story appeared in Volume 85, Issue 45

Facing generic competition and a drop in sales of its diabetes drug Avandia, GlaxoSmithKline has launched a $3.1 billion operational cost reduction program that is expected to result in annual pretax savings of up to $1.5 billion by 2010. GSK says the initiative will improve efficiency in R&D, manufacturing, and sales. The company will pare its manufacturing sites and "streamline" R&D with an increased focus on biopharmaceuticals, oncology, vaccines, and neuroscience. GSK announced the plan as part of its third-quarter earnings. Sales of Avandia dropped 38% for the quarter to about $467 million.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.